Benefits of Secukinumab in Ankylosing Spondylitis May Persist at Two Years Benefits of Secukinumab in Ankylosing Spondylitis May Persist at Two Years

Secukinumab appears to improve clinical and radiographic outcomes of ankylosing spondylitis (AS) through two years of therapy, according to new results from the MEASURE 1 study.Reuters Health Information
Source: Medscape Orthopaedics Headlines - Category: Orthopaedics Tags: Rheumatology News Source Type: news